独家丨璨辰科技完成数千万天使系列融资，AI 虚拟器官仿真平台加速落地
Ranking
No observed public metrics; popularity remains neutral/archived.
Merged summary
TL;DR - Chinese startup CANCHEN TECH (璨辰科技) raised tens of millions of RMB across seed/angel rounds to build a full-scale AI "virtual organ" digital-twin simulation platform aimed at replacing parts of traditional animal testing in preclinical drug evaluation. It matters because regulators (China's CDE, plus FDA/EMA/MHRA) are now opening the door to New Approach Methodologies, making simulation-based evidence commercially viable.
- Platform is a three-layer stack: a multi-omics foundation model at the base, digital twins of individual organs (brain, gut, liver) in the middle, and multi-organ/whole-body lifecycle inference on top; the team emphasizes causal modeling via dynamical systems and biological constraints rather than parameter scaling.
- Claimed technical differentiator is a closed loop of simulation → wet-lab → preclinical validation, with cross-scale organ twins applied at scale to developmental toxicity assessment and neurological disease mechanism studies, and risk predictions cross-checked against in vivo models and partner hospitals.
- Prior work includes first full-cycle 3D dynamic modeling of mammalian embryos, with results published in Cell; infrastructure partnerships cover a dedicated virtual-organ training data platform, a southwest national intelligent computing center, BGI's Sanya life science institute, and tertiary hospitals for newborn developmental disease screening.
- Investors include 东方富海, 松禾资本, 零以创投, 水木清华基金, 启迪之星创投, 启繁资本 and 南山战新投; the article notes regulatory validation standards and data-loop maturity remain unresolved industry-wide.
Sources (1)
独家丨璨辰科技完成数千万天使系列融资，AI 虚拟器官仿真平台加速落地
TL;DR - Chinese startup CANCHEN TECH (璨辰科技) raised tens of millions of RMB across seed/angel rounds to build a full-scale AI "virtual organ" digital-twin simulation platform aimed at replacing parts of traditional animal testing in preclinical drug evaluation. It matters because regulators (China's CDE, plus FDA/EMA/MHRA) are now opening the door to New Approach Methodologies, making simulation-based evidence commercially viable.
- Platform is a three-layer stack: a multi-omics foundation model at the base, digital twins of individual organs (brain, gut, liver) in the middle, and multi-organ/whole-body lifecycle inference on top; the team emphasizes causal modeling via dynamical systems and biological constraints rather than parameter scaling.
- Claimed technical differentiator is a closed loop of simulation → wet-lab → preclinical validation, with cross-scale organ twins applied at scale to developmental toxicity assessment and neurological disease mechanism studies, and risk predictions cross-checked against in vivo models and partner hospitals.
- Prior work includes first full-cycle 3D dynamic modeling of mammalian embryos, with results published in Cell; infrastructure partnerships cover a dedicated virtual-organ training data platform, a southwest national intelligent computing center, BGI's Sanya life science institute, and tertiary hospitals for newborn developmental disease screening.
- Investors include 东方富海, 松禾资本, 零以创投, 水木清华基金, 启迪之星创投, 启繁资本 and 南山战新投; the article notes regulatory validation standards and data-loop maturity remain unresolved industry-wide.